Evotec (EVO) to Release Quarterly Earnings on Wednesday

Evotec (NASDAQ:EVO) is anticipated to post its Q4 2025 resultson Wednesday, April 8th. Analysts expect Evotec to post earnings of $0.1126 per share and revenue of $276.9370 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, April 8, 2026 at 6:00 AM ET.

Evotec Stock Up 5.9%

Shares of NASDAQ EVO opened at $2.50 on Wednesday. Evotec has a twelve month low of $2.31 and a twelve month high of $4.80. The business has a fifty day simple moving average of $3.15 and a two-hundred day simple moving average of $3.35. The company has a quick ratio of 2.03, a current ratio of 2.12 and a debt-to-equity ratio of 0.48.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in EVO. Marshall Wace LLP bought a new position in shares of Evotec in the 4th quarter worth $40,000. BNP Paribas Financial Markets grew its stake in Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the last quarter. Bank of America Corp DE grew its stake in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. XTX Topco Ltd raised its holdings in Evotec by 25.1% in the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after purchasing an additional 3,709 shares in the last quarter. Finally, HRT Financial LP bought a new position in Evotec in the fourth quarter worth about $72,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EVO. Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Wall Street Zen raised shares of Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Finally, Berenberg Bank began coverage on shares of Evotec in a report on Tuesday, February 3rd. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.00.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.